Fundamental Analysis of Myovant Sciences Ltd(NYSE:MYOV) stock

Fundamental Rating

Taking everything into account, MYOV scores 2 out of 10 in our fundamental rating. MYOV was compared to 588 industry peers in the Biotechnology industry. MYOV may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, MYOV is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MYOV has reported negative net income.

In the past year MYOV has reported a negative cash flow from operations.

In the past 5 years MYOV always reported negative net income.

In the past 5 years MYOV reported 4 times negative operating cash flow.

1.2 Ratios

The profitability ratios for MYOV are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of MYOV (73.03%) is better than 84.43% of its industry peers.

The Profit Margin and Operating Margin are not available for MYOV so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	73.03%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MYOV does not have a ROIC to compare to the WACC, probably because it is not profitable.

MYOV has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, MYOV has more shares outstanding

The debt/assets ratio for MYOV is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -2.98, we must say that MYOV is in the distress zone and has some risk of bankruptcy.

MYOV has a worse Altman-Z score (-2.98) than 60.53% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-2.98

ROIC/WACCN/A

WACC7.64%

2.3 Liquidity

MYOV has a Current Ratio of 1.57. This is a normal value and indicates that MYOV is financially healthy and should not expect problems in meeting its short term obligations.

MYOV's Current ratio of 1.57 is on the low side compared to the rest of the industry. MYOV is outperformed by 84.43% of its industry peers.

A Quick Ratio of 1.45 indicates that MYOV should not have too much problems paying its short term obligations.

With a Quick ratio value of 1.45, MYOV is not doing good in the industry: 83.96% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.57
Quick Ratio	1.45

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.67% over the past year.

The Revenue has grown by 91.46% in the past year. This is a very strong growth!

EPS 1Y (TTM)22.67%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q13.24%

Revenue 1Y (TTM)91.46%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q84.11%

3.2 Future

MYOV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.08% yearly.

MYOV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.18% yearly.

EPS Next Y19.42%

EPS Next 2Y25.59%

EPS Next 3Y20.67%

EPS Next 5Y25.08%

Revenue Next Year81.1%

Revenue Next 2Y53.4%

Revenue Next 3Y43.72%

Revenue Next 5Y45.18%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MYOV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MYOV. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MYOV's earnings are expected to grow with 20.67% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y25.59%

EPS Next 3Y20.67%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MYOV!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

Myovant Sciences Ltd

NYSE:MYOV (3/9/2023, 7:04:00 PM)

After market: 26.98 0 (0%)

26.98

-0.01 (-0.04%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.62B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	73.03%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.94

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.57
Quick Ratio	1.45
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)22.67%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y19.42%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)91.46%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

Myovant Sciences Ltd (MYOV)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens